Zevra Therapeutics (DB:1GDA) - Stock Price, News & Analysis

1GDA Stock Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. More details

1GDA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 94.3% below our estimate of its fair value

Earnings are forecast to grow 73.47% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Zevra Therapeutics, Inc. Competitors

PharmaSGP Holding

XTRA:PSG

€280.6m

Dermapharm Holding

XTRA:DMP

€2.0b

Pierrel

DB:2FJ0

€92.8m

Apontis Pharma

XTRA:APPH

€80.3m

Price History & Performance

Summary of all time highs, changes and price drops for Zevra Therapeutics
Historical stock prices
Current Share Price	US$8.60
52 Week High	US$8.60
52 Week Low	US$3.80
Beta	1.93
11 Month Change	15.44%
3 Month Change	n/a
1 Year Change	112.87%
33 Year Change	18.62%
5 Year Change	31.10%
Change since IPO	-96.93%

Recent updates

Shareholder Returns

	1GDA	DE Pharmaceuticals	DE Market
7D	2.4%	-1.2%	-0.02%
1Y	112.9%	-20.1%	8.2%

Return vs Industry: 1GDA exceeded the German Pharmaceuticals industry which returned -22% over the past year.

Return vs Market: 1GDA exceeded the German Market which returned 7.4% over the past year.

Price Volatility

Is 1GDA's price volatile compared to industry and market?
1GDA volatility
1GDA Average Weekly Movement	12.1%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 1GDA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1GDA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2006	67	Neil McFarlane	zevra.com

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Zevra Therapeutics, Inc. Fundamentals Summary

How do Zevra Therapeutics's earnings and revenue compare to its market cap?
1GDA fundamental statistics
Market cap	€467.98m
Earnings (TTM)	-€86.10m
Revenue (TTM)	€23.52m

20.9x

P/S Ratio

-5.7x

P/E Ratio

Is 1GDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GDA income statement (TTM)
Revenue	US$24.49m
Cost of Revenue	US$8.05m
Gross Profit	US$16.44m
Other Expenses	US$106.10m
Earnings	-US$89.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.68
Gross Margin	67.13%
Net Profit Margin	-366.14%
Debt/Equity Ratio	84.4%

How did 1GDA perform over the long term?

See historical performance and comparison

1GDA Stock Overview

Rewards

Risk Analysis

Zevra Therapeutics, Inc. Competitors

XTRA:PSG

€280.6m

XTRA:DMP

€2.0b

DB:2FJ0

€92.8m

XTRA:APPH

€80.3m

Price History & Performance

Recent News & Updates

Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C

Third quarter 2024 earnings released: US$0.69 loss per share (vs US$0.40 loss in 3Q 2023)

Zevra Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

Second quarter 2024 earnings released: US$0.48 loss per share (vs US$0.15 loss in 2Q 2023)

Zevra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000005 million.

Recent updates

Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C

Third quarter 2024 earnings released: US$0.69 loss per share (vs US$0.40 loss in 3Q 2023)

Zevra Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

High number of new directors

Second quarter 2024 earnings released: US$0.48 loss per share (vs US$0.15 loss in 2Q 2023)

Zevra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000005 million.

New major risk - Shareholder dilution

Zevra Therapeutics, Inc. Announces FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Independent Director recently bought €54k worth of stock

Zevra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Zevra Therapeutics, Inc. Expands Executive Leadership Team

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.34 loss in 1Q 2023)

Zevra Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Zevra Therapeutics, Inc., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in FY 2022)

Zevra Therapeutics, Inc. Announces Top-Line Data from the Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia

Zevra Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Forecast breakeven date pushed back to 2026

Zevra Therapeutics, Inc. Appoints Alvin Shih to the Board of Directors

Zevra Therapeutics, Inc. Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics, Inc. Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

New minor risk - Shareholder dilution

No longer forecast to breakeven

Zevra Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zevra Therapeutics, Inc. Announces Executive Changes

Zevra Therapeutics, Inc. Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of Sdx, the Sole Active Pharmaceutical Ingredient in Kp1077, in Healthy Volunteers At Psych Congress 2023

New minor risk - Profitability

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.70 loss in 2Q 2022)

No longer forecast to breakeven

Zevra Therapeutics, Inc. Announces Board Changes

High number of new directors

First quarter 2023 earnings released: US$0.34 loss per share (vs US$0.054 loss in 1Q 2022)

Zevra Therapeutics, Inc. Announces Change of CEO, Effective June 1, 2023

Full year 2022 earnings released: US$1.21 loss per share (vs US$2.11 loss in FY 2021)

KemPharm, Inc. Appoints Daniel Gallo as Senior Vice President of Medical Affairs and Advocacy

KemPharm, Inc., Annual General Meeting, Apr 25, 2023

KemPharm, Inc. Announces Promotion of Sven Guenther to Chief Scientific Officer and Christal Mickle to Chief Product Development Officer

KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

KemPharm, Inc. Appoints Christopher Posner as New Independent Director

KemPharm, Inc. Announces That the U.S. Food and Drug Administration (The FDA) Grants the Orphan Drug Designation to Serdexmethylphenidate

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.19 loss per share (vs US$0.05 loss in 3Q 2021)

Kempharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (Sdx)

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.40 loss in 2Q 2021)

Forecast breakeven date pushed back to 2024

KemPharm, Inc.(NasdaqGS:KMPH) dropped from Russell Microcap Value Index

First quarter 2022 earnings released: US$0.054 loss per share (vs US$2.49 loss in 1Q 2021)

KemPharm, Inc., Annual General Meeting, Jun 28, 2022

KemPharm, Inc. Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Forecast breakeven date pushed back to 2023

Kempharm, Inc. Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate

Forecast breakeven date pushed back to 2023

Full year 2021 earnings released: US$2.11 loss per share (vs US$3.21 loss in FY 2020)